Table 7.
Concepts of measurement assessed according to treatment class.
| PRO MEASUREMENT CONCEPT | CDK INHIBITORS (n = 11) n (%) | HER2+ (n = 11) n (%) | ER+ (n = 8) n (%) | TRIPLE-NEGATIVE (n = 7) n (%) | Src INHIBITORS (n = 1) n (%) |
|---|---|---|---|---|---|
| Quality of life | 3 (27.2%) | 11 (100.0%) | 5 (62.5%) | 6 (85.7%) | – |
| Symptoms | 6 (54.5%) | 5 (45.5%) | 3 (37.5%) | 4 (57.1%) | 1 (100.0%) |
| Health status | 6 (54.5%) | – | 1 (12.5%) | 1 (14.3%) | – |
| Depression | 1 (9.1%) | – | 2 (25.0%) | 1 (14.3%) | – |
| Functional status | 1 (9.1%) | – | 1 (12.5%) | 2 (28.5%) | – |
| Health-related quality of life | 2 (18.1%) | – | 2 (25.0%) | – | – |
| Anxiety | 1 (9.1%) | – | 2 (25.0%) | – | – |
| Additional cancer concerns | – | 1 (9.1%) | – | 1 (14.3%) | – |
| Economic impact | – | 1 (9.1%) | – | 1 (14.3%) | – |
| Fatigue | – | 1 (9.1%) | – | 1 (14.3%) | – |
| Discomfort | – | – | 1 (12.5%) | – | – |
| Health resource utilization | – | 1 (9.1%) | – | – | – |
| Sleep quality | – | – | – | 1 (14.3%) | – |
| Toxicity burden | 1 (9.1%) | – | – | – | – |